1. Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O’Connell MJ, Frytak S (1976) Phase II study of VP16-213 versus dihydrogalactitol in patients with metastatic malignant melanoma. Cancer Treat Rep 60:1681–1682
2. Allen LM, Shirley M (1977) Mechanism of cellular transport of two epipodophyllotoxin glucopyranoside derivatives, VM 26 and VP 16. Proc Am Assoc Cancer Res 18:22
3. Allen, LM (1978) Cellular pharmacokinetics of two epipodophyllotoxin glucopyranoside derivatives, VM 26 and VP 16: Uptake in the presence and absence of human serum albumin. Proc Am Assoc Cancer Res 19:125
4. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D, Koons LS (1978) Phase II trial of VM 26 in patients with metastatic malignant melanoma. Cancer Treat Rep 62:445–447
5. Bender RA, Anderson T, Fisher RI, Yong RC (1978) Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. Am J Hematol 5:203–209